Rani Therapeutics Reports Q2 2026 Results; RT-114 Phase 1a Data Positive

Rani Therapeutics reported its second quarter 2026 financial results, alongside significant corporate and clinical updates. The company announced positive initial Phase 1a data for RT-114, demonstrating oral bioavailability greater than 150% compared to subcutaneous dosing, and has dosed the first participants in the Phase 1a expansion cohort. Rani also completed a $20 million registered direct offering, expanded its obesity pipeline through a new collaboration with PegBio, and made key management appointments. For Q2 2026, the net loss decreased to $8.4 million from $11.2 million year-over-year, and contract revenue reached $1.7 million.